You Junqi, Xia Haoming, Huang Ziyue, He Risheng, Zhao Xudong, Chen Jiali, Liu Sidi, Xu Yi, Cui Yunfu
Department of Pancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Department of Anesthesiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Front Oncol. 2023 Jul 20;13:1204715. doi: 10.3389/fonc.2023.1204715. eCollection 2023.
Hepatocellular carcinoma (HCC) is a highly malignant tumor that carries a significant risk of morbidity and mortality. This type of cancer is prevalent in Asia due to the widespread presence of risk factors. Unfortunately, HCC often goes undetected until it has reached an advanced stage, making early detection and treatment critical for better outcomes. Alpha-fetoprotein (AFP) is commonly used in clinical practice for diagnosing HCC, but its sensitivity and specificity are limited. While surgery and liver transplantation are the main radical treatments, drug therapy and local interventions are better options for patients with advanced HCC. Accurately assessing treatment efficacy and adjusting plans in a timely manner can significantly improve the prognosis of HCC. Non-coding RNA gene transcription products cannot participate in protein production, but they can regulate gene expression and protein function through the regulation of transcription and translation processes. These non-coding RNAs have been found to be associated with tumor development in various types of tumors. Noncoding RNA released by tumor or blood cells can circulate in the blood and serve as a biomarker for diagnosis, prognosis, and efficacy assessment. This article explores the unique role of circulating noncoding RNA in HCC from various perspectives.
肝细胞癌（HCC）是一种高度恶性的肿瘤，具有很高的发病和死亡风险。由于危险因素广泛存在，这种癌症在亚洲很常见。不幸的是，HCC在达到晚期之前往往未被发现，因此早期检测和治疗对于获得更好的治疗效果至关重要。甲胎蛋白（AFP）在临床实践中常用于诊断HCC，但其敏感性和特异性有限。虽然手术和肝移植是主要的根治性治疗方法，但药物治疗和局部干预对于晚期HCC患者是更好的选择。准确评估治疗效果并及时调整治疗方案可显著改善HCC的预后。非编码RNA基因转录产物不能参与蛋白质合成，但它们可以通过调控转录和翻译过程来调节基因表达和蛋白质功能。这些非编码RNA已被发现与各种类型肿瘤的发生发展有关。肿瘤或血细胞释放的非编码RNA可在血液中循环，并作为诊断、预后和疗效评估的生物标志物。本文从多个角度探讨循环非编码RNA在HCC中的独特作用。
